Samsung Bioepis Biosimilars Report Slams ‘Stagnant’ US Adalimumab Uptake
Figures From Q4 Reveal Humira Rivals Have Captured Just 2% Of The Market
In its latest biosimilar market report, Samsung Bioepis laments the lack of uptake for biosimilar rivals to Humira, despite a slew of challengers arriving in the US last year.
